Posted by Michael Wonder on 26 Jun 2019
New Zealand falling behind rest of world in cancer treatment
26 June 2019 - The management of New Zealand’s most common blood cancer, myeloma, is falling behind the rest of the world, putting lives at unnecessary risk of this incurable but treatable disease.
This is a concerning finding of the Burden of Multiple Myeloma economics report released today by Myeloma New Zealand, who are calling for improved access to best-practice treatment options for the estimated 2,500 New Zealanders living with myeloma.
According to Dr Ken Romeril, clinical haematologist and Chief Executive, Myeloma New Zealand, more needs to be done to ensure New Zealanders living with myeloma receive the same access to innovative myeloma treatments already available in other counties.
